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The aim of this study was to investigate the potential of surface plasmon resonance
(SPR) spectroscopy for the measurement of real-time ligand-binding affinities and kinetic
parameters for GPR17, a G protein-coupled receptor (GPCR) of major interest in
medicinal chemistry as potential target in demyelinating diseases. The receptor was
directly captured, in a single-step, from solubilized membrane extracts on the sensor
chip through a covalently bound anti-6x-His-antibody and retained its ligand binding
activity for over 24 h. Furthermore, our experimental setup made possible, after a
mild regeneration step, to remove the bound receptor without damaging the antibody,
and thus to reuse many times the same chip. Two engineered variants of GPR17,
designed for crystallographic studies, were expressed in insect cells, extracted from
crude membranes and analyzed for their binding with two high affinity ligands: the
antagonist Cangrelor and the agonist Asinex 1. The calculated kinetic parameters and
binding constants of ligands were in good agreement with those reported from activity
assays and highlighted a possible functional role of the N-terminal residues of the receptor
in ligand recognition and binding. Validation of SPR results was obtained by docking and
molecular dynamics of GPR17-ligands interactions and by functional in vitro studies. The
latter allowed us to confirm that Asinex 1 behaves as GPR17 receptor agonist, inhibits
forskolin-stimulated adenylyl cyclase pathway and promotes oligodendrocyte precursor
cell maturation and myelinating ability.
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INTRODUCTION
The molecular targets for about 50–60% of currently validated
drugs are membrane proteins, such as G-protein coupled
receptors (GPCRs); this class of proteins still features the
main target in drug discovery programs (Hauser et al., 2017;
Ribeiro-Oliveira et al., 2019). To this purpose, a range of
chemical, biochemical and biophysical techniques are available
for the characterization of ligand binding and for screening
libraries of compounds searching for potential drug candidates.
One of such techniques is surface plasmon resonance (SPR)
spectroscopy, a label-free technique which enables measurement
of real-time ligand-binding affinities and kinetics using relatively
small amounts of membrane protein in a native or native-like
environment (Olaru et al., 2015).
The typical SPR experimental protocol involves the direct
binding of ligands on an immobilized target, which is usually
a pure protein. Measuring the binding kinetics and affinities of
ligands to intact membrane proteins by SPR is a challenging
task, largely because of the inherent difficulties in capturing
membrane proteins on chip surfaces while retaining their native
conformation (Maynard et al., 2009; Patching, 2014) either in
the original membrane environment or in membrane-mimicking
structures, such as for example, lipid bilayer disks (Lundquist
et al., 2010). An alternative method consists in capturing the
detergent-solubilized receptor, engineered with a tag (such as
multiple histidine residues or a short peptide sequence), with
an appropriate antibody which has been previously covalently
immobilized onto a chip through covalent bonding (Rich et al.,
2011).
A gap still holds between the consolidated SPR technology
and the request for innovative and robust immobilization
methods for GPCRs. Indeed, in face of their importance
as pharmacological targets, the intrinsic instability of GPCRs
when extracted from the lipid milieu in the unligated form,
makes them very challenging objects for SPR techniques, with
only few examples of successful processing reported so far
(i.e., neurotensin receptor type 1, chemokine receptor type 5
(CXCR5), β1 adrenergic receptor and purified adenosine 2A
receptor) (Congreve et al., 2011; Adamson and Watts, 2014;
Aristotelous et al., 2015; Bocquet et al., 2015; Chu et al., 2015).
Among the GPCR receptors, GPR17 holds a place of special
interest in medicinal chemistry, being a key regulator of
oligodendrocyte precursor cells (OPC) maturation (Fumagalli
et al., 2016; Alavi et al., 2019). From a structural point of
view, several binding sites have been described, which are
the target of different classes of highly heterogeneous ligands
(i.e., uracil nucleotides, cysteinyl leukotrienes, chemokines, and
oxysterols) (Ciana et al., 2006; Eberini et al., 2011; Sensi
et al., 2014; Parravicini et al., 2016). From a functional
point of view, GPR17 is one of the most interesting targets
for neurodegenerative disorders, since it crucially modulates
the maturation of oligodendrocytes, the cells responsible for
the production of myelin that, in turn, ensheates neuronal
endings, thus allowing nerve impulse transmission. Myelin
preservation and reconstruction accelerate neuronal repair and
neurological recovery, and indeed represents a highly innovative
approach to diseases, such as multiple sclerosis, Alzheimer’s and
cerebral ischemia (Fumagalli et al., 2015; Bonfanti et al., 2017;
Seyedsadr and Ineichen, 2017). Therefore, new, more selective
and pharmacokinetically suitable molecules are presently needed
to translate promising preclinical data into patients care.
[35S]GTPγS binding-assay is an analytical method that has
been used to investigate the activity of potential new GPR17
ligands with high accuracy and selectivity. The assay uses a GTP
analog ([35S]GTPγS) which cannot be hydrolyzed by the GTPasic
activity of the Gα subunit. Thus, GPCR activation or inhibition
can be quantified by measuring the amount of radiolabelled GTP
bound to the receptor-G protein complex (Harrison and Traynor,
2003). However, this standard functional assay does not provide
any information on the direct molecular interaction between the
ligand and the receptor.
In a previous work, frontal affinity chromatography-mass
spectrometry (FAC-MS) was used to directly measure the
direct binding of ligands to GPR17. In this assay, a liquid
stationary phase containing membrane preparations from
GPR17-expressing cells was coupled to an electrospray mass
spectrometer as detector. Through the continuous infusion into
the column of a solution of nucleotide analog it was possible
to screen a high number of molecules in a single analysis, and
to calculate the interaction between the receptor and different
potential ligands (Calleri et al., 2010). Although this assay proved
to be a powerful tool for the rapid screening of many compounds
and for the assessment of low-to-medium affinity ligands, the
approach is less effective in the characterization of the binding
in the low nanomolar range.
Here, we report an SPR-based protocol that allowed us to
efficiently immobilize two engineered variants of GPR17 on a
sensor chip and to detect and measure the direct binding of
two high affinity ligands. The calculated kinetic parameters and
binding constants are in good agreement with those previously
reported by activity assays and highlight a possible role of the
N-terminal residues of receptor in ligand recognition.
MATERIALS AND METHODS
Reagents and Instrumentation
Surface Plasmon Resonance (SPR) experiments with the ligands
were performed at 25◦C using a Pioneer AE optical biosensor
(Molecular Devices-ForteBio) equipped with a PCH sensor
chip (linear polycarboxylate hydrogel), and equilibrated with
running buffer 20mM Hepes, pH 7.5, 0.15M NaCl, 0.03%
Dodecyl Maltoside (DDM) and Cholesteryl Hemisuccinate
(CHS) solution (DDM/CHS ratio 5:1) (with 1% DMSO, in the
experiment with the agonist compound).
The GPR17 antagonist Cangrelor in its purified enantiomer
(dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methyl
sulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-
9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxy
phosphoryl]methyl]phosphonic acid) was a kind gift of
Medicines Company (Parsippany, NJ, USA) and agonist Asinex
1 (2-[[5-(2-methoxyphenyl)-4-(4-methoxyphenyl)-4H-1,2,4-
triazol-3-yl]thio]-N-phenyl-propanamide; CAS 483283-39-2,
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previously published as ASN 02563583), was purchased from
Ambinter (c/o Greenpharma, Orlèans, France) as racemic
mixture. The detergents were from Anatrace, the anti-His6
antibody and other laboratory reagents were from Sigma.
Protein Engineering
The cDNA sequence of wild type human GPR17 receptor (short
isoform, Uniprot id: Q13304-2) cloned into the pcDNA3.1
vector was used as template for DNA amplification. A modified
cysteine-free version of T4 lysozyme (T4L) was inserted in the
third intracellular loop (IC3), replacing residues 224–229, by
short overlap extension (SOE) PCR. Briefly, three overlapping
fragments encoding residues 1–223 of GPR17, 2–160 of T4L
and 230–339 of GPR17, respectively were amplified by PCR
and used as templates for a final round of amplification. The
primers were designed to generate the full length (GPR17-T4
1-339) and a shorter variant lacking the first 15 amino acids
(GPR17-T4 16-339) of the T4L chimeric receptor fused with a
TEV cleavage site and a 10XHis-tag at the C-terminus. The two
constructs were further modified by introducing the D2937.49N
mutation using the QuikChange II Site-Directed Mutagenesis
Kit (Stratagene). The resulting sequences were cloned into the
pFastBac vector (Invitrogen).
Expression and Purification of GPT17
Variants From Insect Cells
High titer recombinant baculovirus stocks (>108 pfu/mL) of
the two variants were obtained with the Bac-toBac TOPO
Expression system (Invitrogen) in SF9 insect cells. For protein
expression, suspension cultures of SF9 or High Five cells at
density of 2 × 106 cells/mL in suitable serum-free medium were
infected with the virus at a multiplicity of infection (m.o.i.)
of 3. After 48 h, cells were collected by centrifugation and
resuspended in a hypotonic Lysis Buffer (LB) composed of
10mM HEPES, pH 7.5, 10mM MgCl2, 20mM KCl added with
a protease inhibitor cocktail (Roche). The cells were disrupted
by Dounce homogenization in a glass potter, the membrane
fraction collected by high speed (45,000 rpm) centrifugation
for 45min and washed twice with the same buffer. After an
additional high salt wash (LB with 1M NaCl), the membranes
were resuspended in LB containing 20% glycerol at total protein
concentration of 3 mg/mL, flash-frozen in liquid nitrogen and
stored at −80◦C until use. Purified membranes were thawed on
ice in presence of 1 mg/mL iodoacetamide, 50µM Cangrelor
and protease inhibitors, mixed with an equivalent volume of 2×
Solubilization Buffer (SB, 100mM HEPES pH 7.5, 0.6M NaCl,
2% DDM/0.4% CHS) and stirred at 4◦C for 2 h. The insoluble
material was removed by centrifugation and the supernatant,
added with 20mM imidazole, was incubated overnight at 4◦C
with TALON IMAC resin (Clontech) (0.5mL of resin for 300mL
of initial cell culture). The resin was extensively washed with
15–20 column volumes of Wash Buffer (50mM HEPES pH 7.5,
0.3M NaCl, 0.05% DDM/0.01%CHS, 10µM Cangrelor, 50mM
imidazole) and the bound proteins eluted with 2 column volumes
of Elution Buffer (50mM Hepes pH 7.5, 0.3M NaCl, 0.05%
DDM/0.01% CHS, 10µM Cangrelor, 300mM imidazole). The
purity of the final preparations was checked by SDS-PAGE and
Western Blot with an anti-His6 monoclonal antibody (Sigma).
The apo proteins were purified with the same protocol in the
absence of Cangrelor. The presence of glycosylation was assessed
by PNGase F digestion on denatured samples (laboratory-made
reagents). The monodispersity of GPR17 samples in absence or
in presence of 10µM Cangrelor was evaluated by size exclusion
chromatography on a 10/30 G200 column equilibrated in 20mM
HEPES pH 7.5, 0.15M NaCl, 0.05% DDM/0.01% CHS.
Antibody Immobilization
An antibody specific for His6-tagged proteins was immobilized
on the Chip surface using amine coupling chemistry (Jonsson
and Malmqvist, 1992; Lundquist et al., 2010). Briefly, flow
cells were activated for 4min by injecting 40 µL of 1:1 ratio
of 100mM N-hydroxysuccinimide (NHS)/400mM ethyl-3(3-
dymethylamino) propyl carbodiimide (EDC). The antibody
solution (50µL of 100µg/mL antibody and 300µL of NaAcetate,
pH 4.5) was then injected for 10min at 10 µL/min, followed
by a 70 µL injection of ethanolamine 1M, pH 8.0, to block any
remaining activated groups on the surface. Approximately 18,000
RUs of antibody were immobilized on the three channels of the
sensor chip. The immobilization step was performed in HBS
buffer (Hepes 20mM, pH 7.4, NaCl 150mM, Tween 20 0.005%).
Capturing the Solubilized Receptor
Engineered 10xHis-tag GPR17 receptor, expressed from two
different constructs (1–339 and 16–339) in two different cell
lines (H5 and SF9), was captured on the antibody for the
SPR experiments. The C-terminal 10xHis-tag, situated in the
intracellular region of the receptor, can be captured by the
antibody allowing the extracellular N-terminal part, involved in
ligand recognition, to be free to interact with the ligand.
Briefly, a frozen aliquot of crude membrane extract (0.1mL)
was mixed with 5 µL of Protease Inhibitor Cocktail 100×
(Sigma) and incubated on ice for 30min. An equal volume of
solubilization buffer 2× (100mM Hepes, pH 7.5, 0.6M NaCl,
2% DDM/CHS 10:2) was then added to the membrane extract
and incubated 2.5 h at 4◦C, under gentle rotation. The membrane
preparation was then centrifuged for 30min at 14,000 rpm and
the supernatant collected. Crude cell supernatant (diluted 1/3 in
MES 50mM, pH 6.0, 1% DDM/CHS 5:1) was injected (flux 5
µL/min) across the PCH sensor (channels 1 and 3) where the
anti-His6 antibody was previously immobilized. The chip surface
was washed for several hours with running buffer (flux 150
µL/min) to remove non-specifically bound supernatant debris.
Alternatively, few short injections (15 s, flux 50 µL/min) of NaCl
0.5M in DDM/CHS 1% can be effective to quickly remove the
debris. After the cleaning procedure, ∼500 RU of solubilized
receptor were captured on channels 1 and 3 (channel 2 was used
as reference).
The stability of the protein-antibody surface was
demonstrated by the flat baseline achieved at the beginning
of each sensogram. Once immobilized on the chip surface,
GPR17 was found to maintain its activity over at least 24 h.
Afterwards, the receptor was easily removed by few injections
of regeneration solution (50mM NaOH injected for 30 s at 50
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µL/min). After the regeneration step, the chip surface was ready
for capturing freshly solubilized receptor for new experiments.
Kinetic Analysis of Cangrelor and Asinex 1
The GPR17 antagonist Cangrelor and the agonist Asinex 1,
dissolved in running buffer, were tested in serial dilutions for
binding to GPR17, from 1µM to 3.125 nM for Asinex 1 and from
2µM to 7.81 nM for Cangrelor (see Supplementary Figures S1–
S4). Analytes were injected at a flow rate of 25 µL/min for 1min
over the three channels. Several buffer blanks were injected for
double referencing. The regeneration of the surfaces between
binding cycles was not necessary because the analytes completely
dissociate in the 240 s dissociation phase. A DMSO calibration
was performed for Asinex 1 [0.5–1.5% (vol/vol) DMSO] to
correct for bulk refractive index shifts (Frostell-Karlsson et al.,
2000). All the experiments were carried out in duplicate.
All sensorgrams were processed by using double referencing
(Myszka and Morton, 1998). Formation of the complex
between GPR17 and ligands was indicated by the increase in
resonance units (RUs) relative to baseline upon injection of each
compound at each concentration (Supplementary Figures S1–
S4). To obtain the kinetic and affinity constants the corrected
response data were fed to the program QDAT. A kinetic
analysis of each ligand/analyte interaction was obtained by
fitting the response data to a 1:1 bimolecular interaction mode
(Figures 3A–D). Constants reported in the table of Figure 3
represent the average of two independent analyses of each
GPR17/analyte interaction.
In silico Molecular Modeling and Ligand
Docking
All the computational procedures, except for the molecular
dynamics (MD) simulations, were carried out with the Molecular
Operating Environment software (MOE2019.0101 Chemical
Computing Group, Montreal, Canada), using the Amber12:EHT
force field with the reaction field electrostatics treatment.
The MD simulation of the GPR17-T4 1-339 variant and the
procedures required for the preparation of the system were
performed using the Schrödinger suite (Schrödinger, New York,
NY, 2018).
Homology Modeling
The homology modeling procedure was performed using the
MOE “Homology Model” program, starting from a multiple
sequence alignment of the primary structures of a subgroup
of structurally related class-A GPCRs, as previously described
(Sensi et al., 2014; Parravicini et al., 2016). The multiple sequence
alignment was performed using the TM-Coffee algorithm, a
module of the T-Coffee package optimized for transmembrane
proteins (Chang et al., 2012).
The tridimensional structure (3D) of the human GPR17
receptor in its wild-type formwas built by comparativemodeling,
using as template the 2.7 Å resolution X-ray structure of the
human P2Y1 receptor deposited in RCSB Protein Data Bank
[PDB, code: 4XNW (Zhang et al., 2015)]. The GPR17-T4 1-
339 variant was generated by a chimeric approach according
to the above alignment, based on its engineered primary
structure, using the structure of P2Y1 for modeling residues
from Thr19-Leu223 and Lys230-Gal290, the structure of the C-
X-C chemokine receptor type 4 (CXCR4) construct for modeling
the T4 lysozyme (T4L) fusion, and the structure of the apelin
receptor for modeling C-terminal domain (residues from Ala29
to Lys315) after structural alignment of the templates. The
specific setting “C-terminal and N-terminal outgap modeling”
was selected to model the N- and C-terminal regions from the
full-length GPR17 sequence.
Low Mode Molecular Dynamics Search
N-terminal conformational search was performed using the
MOE “LowMode MD” search method, by associating different
conformational freedom to different regions of the protein, to
speed-up calculations. In detail, residues from 1 to 19, 20 to 24, 25
to 40/80 to 115/157 to 202/248 to 286 (the upper TM bundle) and
41–79/116–156/203–247/287–319 (the upper TM bundle), were
treated as a rigid body, flexible, fixed and inert. Also, the T4L
was treated as inert. The Low Mode MD was carried out with
standard settings, except for strain energy cutoff, which was set at
100 kcal/mol.
Ligand Docking
Molecular docking simulations were carried out using the MOE
“Dock” program of the “Simulation” module, with a multi-step
procedure useful for a more accurate estimation of the ligand
binding free energy, as previously described (Eberini et al., 2011;
Platonova et al., 2017). The GPR17 binding site was identified
through theMOE “Site Finder” module. The receptor was treated
as rigid for the docking calculations, while conformational
space was sampled for ligands. Briefly, for each ligand 20,000
conformations were generated by sampling their rotatable bonds
and placed using the Triangle Matcher methodology. Duplicate
complexes were removed, and the accepted poses (1,000 for
each ligand), were scored according to the London dG empirical
scoring function, for an estimation of their binding free energy
(Naïm et al., 2007). The 100 top scoring complexes for each
ligand were submitted to a more in-depth refinement step based
on molecular mechanics (MM), in which the final binding free
energy was evaluated using the force-field based GBVI/WSA
1G empirical scoring function to account for solvation effect
(Wojciechowski and Lesyng, 2004). Only the 10 top-scoring
complexes were kept at this stage. The “LigX” procedure was
finally applied to the top-scoring pose to minimize viamolecular
mechanics (MM) both the ligand and the receptor binding site
for a more accurate estimation of ligand affinity. Dissociation
constant (Kd) values computed through this method have
accuracy in the range of one order of magnitude (Eberini et al.,
2008; Galli et al., 2014).
Molecular Dynamics
The preparation of the GPR17-T4 1-339 variant and its
MD simulation were performed using the Desmond software,
implemented in the Schrödinger suite, version 2019.2 (Desmond
Molecular Dynamics System of the D. E. Shaw Research, New
York, NY). Downstream residues belonging to the C-terminal
portion of the receptor (Gly320-Leu339) were removed for MD
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simulations. The GPR17-T4 1-339 model was processed with the
“Protein PreparationWizard” tool in order to assign protonation
states at pH of 7.0, cap C-terminal, optimize H-bond assignment,
andminimize the protein energy. Then, themodel was embedded
in an explicit membrane bilayer using the “System Builder” tool.
In detail, the receptor was oriented into membrane according to
the OPM server prediction (Lomize et al., 2012) into a membrane
model of 123 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) and solvated with 11,104 TIP3P water molecules, in a
cubic box with dimensions of 82 × 71 × 110 Å. The system was
neutralized by adding 21 chloride ions and sodium chloride was
added up to 0.1M concentration. Prior to simulation, the system
was energy-minimized and equilibrated through the relaxation
protocol. The OPLS3 forcefield was used for both the MD
relaxation phase and the productive MD simulations. For the
membrane relaxation phase, the default protocol was applied; the
productive MD was carried out for a total simulation time of 500
ns, with a recording interval for each frame of 500 ps resulting
in a total of 1,000 recorded frames. The MD was performed
under the following conditions: 300K and 1.01325 bar with NPT
ensemble class, Langevin as thermostat and barostat method with
relaxation time of 1 and 2 ps, respectively, semi-isotropic pressure
coupling style, RESPA integrator with timestep for bond-, short-
and long- range bond interactions of 2, 2 and 6 fs, respectively,
and 9 Å as cutoff for short range Coulombic interactions.
Analyses of the trajectories were performed with both Visual
Molecular Dynamics (VMD) analysis tool (Humphrey et al.,
1996) and GROMACS through VMD plugins (Berendsen et al.,
1995).
In vitro Assays on Cell Cultures
The Università degli Studi di Milano–La Statale (Italy) is
compliant with all applicable national (D.Lgs. 26/2014) and
European (Directive 2010/63/EU) regulations, for using animals
in scientific research. All the experiments were approved by
the Animal Care Committee of the Università degli Studi di
Milano–La Statale, which is legally entitled for the use of animals
for scientific purposes and by the Italian Ministry of Health
(Authorization #473/2015-PR, 05/06/2015).
The pharmacological profile of Asinex 1 was assessed in
three different in vitro assays of increasing complexity in
oligodendrocyte precursor cells (OPCs) natively expressing
GPR17. Primary rat OPCs were cultured either alone or in the
presence of mouse DRG neurons, according to a well-established
protocol, previously described in Fumagalli et al. (2015). The
endogenous GPR17 ligands UDP and LTD4 were selected as
reference ligands. For more details on culture preparation and
analysis, see Supplementary Information.
cAMP Assay
In order to determine the intracellular cAMP levels, primary
purified OPCs were treated with Asinex 1 after 6 days in
culture, when GPR17 expression reaches the maximum peak.
A competitive protein binding method was used following the
procedure previously described (Fumagalli et al., 2015). Briefly,
culture medium was removed, and cells were incubated at 37◦C
for 15min with 400 µL of Neurobasal medium in the presence
of the phosphodiesterase inhibitor Ro20-1724 (20µM). The
concentration-response curve of tested ligands was assessed by
measuring their ability to inhibit cAMP accumulation stimulated
by 10µM forskolin. Asinex 1 was added to cells for 15min at
graded concentration (0.1–50 nM). When required, cells were
preincubated for 10minwith the antagonist Cangrelor. Reactions
were terminated by medium removal and addition of 200
µL of 0.4N HCl. After 30min, lysates were neutralized with
50 µL of 4N KOH, and the suspension was centrifuged at
800× g for 5min. For determination of cAMP, cAMP-binding
protein isolated from bovine adrenal glands was incubated with
[3H]cAMP (2 nM), 50 µL of cell lysate or cAMP standard
(0–16 pmol) at 4◦C for 150min, in a total volume of 300
µL. Bound radioactivity was separated by rapid filtration
through GF/C glass fiber filters and washed twice with 4mL of
50mM Tris-HCl, pH 7.4. Radioactivity was measured by liquid
scintillation spectrometry.
Differentiation and Myelination Assays
GPR17 ligands were tested both in primary OPCs culture and
in OPC/DRG co-cultures to assess their pro-differentiation and
pro-myelination effect, respectively. According to the type of
culture, a specific protocol of treatment was set up. For primary
OPCs, cells were seeded on 13mm poly-D,L-ornithine-coated
coverslips (2 × 104 cells/well) and maintained for 2 days in
Neurobasal medium supplemented with B27 and proliferative
factors (PDGF-BB and bFGF). Afterwards, OPC differentiation
was induced by removing proliferative factors and by adding
T3 and pharmacological treatments with Asinex 1 (1 or 10 nM)
and LTD4 (200 nM), selected as reference compound, were
performed the following day. After 48 h, cells were fixed for
immunocytochemistry (ICC). For OPC/DRG co-cultures, Asinex
1 (10 nM) and UDP (100µM) were added to cultures at day 4.
The pharmacological treatment was repeated every 2 days up to
day 15, when cells were fixed for ICC analysis. For more details,
see Supplementary Information.
RESULTS
Expression and Characterization of
Engineered GPR17 Variants
In order to identify one or more GPR17 variants suitable for
structural studies, we prepared and tested different engineered
constructs of the receptor. A major bottleneck in structure
determination of GPCRs by X-ray crystallography is obtaining
of large amounts (>1–2mg) of highly pure, homogeneous
protein samples that are stable in detergent solutions when
extracted from the lipid environment of the membranes. In
the last decade, a number of protein engineering approaches
have been used to overcome the problem of the intrinsic
instability and conformational heterogeneity of GPCRs. These
include truncations, site-directed mutagenesis, stabilization of
the receptor with specific protein-binding partners (FABs and
nanobodies) and the creation of chimeric constructs in which
flexible loops are replaced with small soluble proteins that
can favor the crystallogenesis process (Piscitelli et al., 2015).
Inserting T4 lysozyme (T4L) in the third intracellular loop (ICL3)
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allowed to obtain the first high resolution crystal structure of
β2-adrenergic receptor (Cherezov et al., 2007; Rosenbaum et al.,
2007); the same strategy was subsequently used for other types
of class A GPCRs (Wu et al., 2010; Granier et al., 2012; Zhang
et al., 2012). More recently, the use of other fusion partners, such
as thermostabilized BRIL or rubredoxin have proven effective in
obtaining diffraction quality crystals of purinergic receptor P2Y12
(Zhang et al., 2014) and P2Y1 (Zhang et al., 2015).
We initially prepared a number of modified variants of
GPR17. Themodifications included a combination of truncations
in different positions near the N- and C- termini and the fusion
of the T4L moiety either at the N-terminal or in ICL3. All these
constructs were used to generate recombinant baculoviruses for
the expression of the receptor in insect cells. Insect cells are
the most common expression system for eukaryotic membrane
proteins and have been used for the production of most of the
mammalian GPCRs crystallized so far (Schneider and Seifert,
2010; Milic´ and Veprintsev, 2015). Small scale expression trials
identified two constructs that could be produced with a good
yield in SF9 cells: the full-length receptor with T4L inserted in
ICL3 (GPR17-T4 1-339) and a shorter version lacking the first
15 amino acids (GPR17-T4 16-339). The expression levels were
further increased by mutating the conserved Asp7.49 (D293) into
Asn, as described for other homologous P2Y receptors (Zhang
et al., 2014, 2015). The modifications introduced in these two
engineered variants are highlighted in the snake-plot displayed
in Figure 1A. After optimization of the expression conditions,
the two variants reached a maximum expression level of about
1–2mg of receptor per liter of culture in both SF9 and High
Five cells, with a slightly higher yield in the latter cell line
(Figure 1B).
The two variants can be effectively extracted from the
isolated membranes with a detergent mix composed of DDM
and CHS and can then be purified by immobilized metal
affinity chromatography (IMAC) exploiting the C-terminal His-
tag as described in the Material and Methods (Figure 1C). A
potential N-glycosylation site (Asn14) is present in the full-length
construct and in fact the protein migrates as a double band in
SDS-PAGE. The higher band disappeared upon treatment with
PNGase F, indicating that a fraction of the receptor is actually
glycosylated. Conversely, the shorter version 16–339 displays
only a single well-defined band.
It is well-known that the binding of a high affinity agonist
or antagonist stabilizes the GPCR in a specific signaling
conformation, and increases the stability and enhances the
size monodispersity of the receptor in detergent solution
(Bertheleme et al., 2013; Grisshammer, 2017). We therefore
assessed the effect of the antagonist Cangrelor on the two
purified variants by size exclusion chromatography (SEC).
Figures 1D,E summarize the results for GPR17-T4 1-339 and
GPR17-T4 16-339, respectively. In both cases, the presence
of Cangrelor increased the fraction of monodisperse receptor
(the peak indicated by the blue arrow in the panels) and
reduced the amount of aggregates that elute in the void volume,
suggesting that these two variants retain the ability to bind
the antagonist with comparable affinity. Although the use of
a stabilizing ligand will be necessary to maximize the yield in
large scale purifications, the presence, albeit in smaller quantities,
of monodisperse apo protein in detergent solution makes these
two constructs suitable for binding experiments and fragment
screening by SPR.
Molecular Modeling and Ligand Docking
In line with the increasing availability of class-AGPCR templates,
thanks to homology approaches on GPR17, our previous studies
have characterized the interactions of GPR17 with its known
endogenous ligands (Parravicini et al., 2008, 2010, 2016; Sensi
et al., 2014). We also identified a first set of entirely new and
highly diverse GPR17 ligands, including the Asinex 1 compound
which was identified within the Asinex Platinum Collection
database (Calleri et al., 2010; Eberini et al., 2011).
To evaluate whether the engineered GPR17 constructs are
thermodynamically stable and still able to recognize ligands,
a chimeric model of the full length GPR17-T4 1-339 variant
was generated by replacing, during the homology modeling
procedure, the ICL3 with the coordinates of the T4 lysozyme
(T4L) fusion of CXCR4 structure (Wu et al., 2010). The structure
of this construct is shown in Figure 2A. For validating the
homology modeling procedure, besides the engineered GPR17
variant, an entirely new GPR17 model was built (Figure 2B),
based on the recently solved X-ray structure of the P2Y1 receptor
(Zhang et al., 2015). In this model, only the three-dimensional
structure (3D) of residues between Thr19 and Leu311 was
predicted, whereas the highly flexible N and C termini were
not generated, since they are not included in the template.
This GPR17 model resulted much more accurate than the
previous ones, due to the closest sequence identity of GPR17
with respect to P2Y1, compared to that shared with all the
other available crystallographic templates among related class-A
GPCRs (26.4%). A pairwise alignment identity matrix between
GPR17 and the primary structures of other related class-AGPCR,
whose structure has been solved (Gacasan et al., 2017), is reported
in Supplementary Figure S5.
Structural alignment of the helical bundle of the
two homology models resulted in a low value of root-
mean-square deviation (RMSD), corresponding to 1.4 Å
(Supplementary Figure S6), suggesting that the use of the T4L
as fusion partner does not impair the general architecture of the
receptor as also found for other crystallized GPCRs (Wu et al.,
2010).
As loop modeling for such flexible regions is known to
be rather inaccurate, putative conformations of the N-terminal
region were computed through an efficient conformational
sampling approach based on the Low Mode MD. LowMode MD
generated only 20 conformations out of the 10,000 allowed for
the N-terminal region, some representative of either the “open”
or the “closed” state of the receptor (Figure 2C), confirming
the ability to efficiently explore the conformational space of the
test region. As shown in Table 1, all the 20 conformations are
associated with negative values of potential energy (E), ranging
from −299.53 to −205.17 kcal/mol; values of 1E between
the lowest- and the highest-energy conformations lower than
100 kcal/mol suggest that all conformations are stable and
biologically relevant.
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FIGURE 1 | Expression and characterization of GPR17 engineered variants. (A) Snake-plot of modified GPR17. The first 15 amino acids (with N-glycosylation on
Asn14) removed in the shorter construct are highlighted in yellow and the D293N mutation in purple. The T4 lysozyme inserted in ICL3 is represented in ribbon model.
The two cysteines linked by disulfide bridge are colored in green. (B) Western blot analysis of GPR17 variants expression in High Five cells. Same amounts of whole
cell extracts were probed with anti-His6-HRP conjugated antibody. (C) SDS-PAGE (top) and western blot (bottom) of purified GPR17-T4 1-339 and GPR17-T4
16-339 before and after treatment with PNGase F. (D,E) SEC profiles of purified GPR17-T4 1-339 (D) and GPR17-T4 16-339 (E) in absence or in presence of a
saturating concentration of Cangrelor. The void volume is indicated with Vo.
The Low Mode MD conformation associated with
the highest (32.3 Å) and lowest (31.3 Å) gyration
radius were selected for further investigation as
representative of the N-terminal open and closed form,
respectively (Table 1).
The closed conformation was then submitted to a classic
MD simulation performed in a heterogeneous water/membrane
native-like environment, allowing unrestrained conformational
sampling for the whole protein and assessing its stability over
the simulation time. Overall, the analysis of the evolution of
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FIGURE 2 | Molecular modeling of GPR17. (A) Chimeric model of GPR17-T4 1–339 (D293N) variant. Topological domains modeled with reference to different
templates, namely P2Y1, CXCR4, and APJ receptor, are represented as gray, yellow, orange ribbons, respectively. The N-terminal region is purple. (B) Homology
model of GPR17 based on P2Y1 receptor as template. Ribbons are colored according to MOE GPCR annotation. (C) Most representative N-terminal conformations
after Low Mode MD sampling. During the Low Mode MD, green ribbons are treated as rigid bodies, yellow ribbons as free to move and gray ribbons as fixed or inert.
(D) Cangrelor binding mode. (E) Asinex 1 binding mode (R enantiomer). (F) Asinex 1 binding mode (S enantiomer). In (E,F), Asinex 1 and Cangrelor docking poses are
superposed to hint to the basis of their competitive antagonism.
both geometrical and energetic parameters over 500 ns of
MD simulation suggests that the GPR17-T4 1–339 variant is
thermodynamically stable and confirms that the presence of
intracellular T4L does not affect extracellular architecture of the
receptor. However, as expected due its intrinsic flexibility, the N-
terminal region is subject to large conformational changes during
MD simulations (Supplementary Figure S7).
To assess the ability of the GPR17 construct to recognize
ligands, the two synthetic compounds Asinex 1 and Cangrelor
were docked into the binding site of both GPR17 “open” and
“closed” form. For Asinex 1, both the R and S enantiomers
were analyzed, since no information on the enantiomeric ratio
is available from the vendor.
In line with previously published data (Eberini et al., 2011),
both ligands were able to bind to the orthosteric binding
site of GPR17 with high affinity (Table 2), supporting the
evidence of a competition between the agonist Asinex 1 and the
antagonist Cangrelor for the same site. Differences in binding
free energy values were found between the docking complexes
obtained with the open and closed conformations of GPR17.
Indeed, all the ligands showed an increased affinity for the
closed receptor conformation (Table 2). To account for solvent
contribution, the Generalized Born implicit solvent model was
applied for computing accurate ligand affinity after relaxation of
each complex binding site. Since both ligands are characterized
by highly hydrophobic moieties, it can be hypothesized that,
in the open conformation, the exposure of these groups to
the extracellular aqueous solvent negatively contributes to the
binding free energy of the complexes, resulting in a loss in affinity
in comparison with the closed form. A 2D plot depicting all the
interactions engaged by the ligands as well as the ligand/receptor
groups exposed to solvent is shown in Supplementary Figure S8.
Figures 2D–F report superposition of the top-scoring poses
obtained for Cangrelor and Asinex 1, respectively.
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TABLE 1 | Low mode MD conformations of the GPR17-T4 1-339 variant.
E (kcal/mol) 1E (kcal/mol) Gyration radius (Å)
−220.96 78.58 31.28
−225.73 73.80 31.29
−222.81 76.72 31.44
−208.99 90.55 31.56
−246.92 52.61 31.58
−217.04 82.50 31.62
−205.17 94.36 31.66
−211.98 87.56 31.68
−218.97 80.56 31.71
−235.83 63.70 31.78
−238.30 61.24 31.85
−212.94 86.59 31.87
−248.32 51.21 31.92
−258.03 41.50 32.05
−220.62 78.91 32.11
−252.47 47.06 32.12
−219.77 79.76 32.19
−282.52 17.02 32.25
−228.87 70.67 32.28
−299.53 0.00 32.33
TABLE 2 | Binding free energy values computed through molecular docking for
GPR17-T41-339.
Docking score
(kcal/mol)
LigX
(kcal/mol)
Kd [M] pKd
OPEN CONFORMATION
Cangrelor −10.23 −13.84 6.5295E-11 10.19
Asinex 1 (R) −8.81 −9.64 8.049E-08 7.09
Asinex 1 (S) −8.71 −9.24 1.5853E-07 6.80
CLOSED CONFORMATION
Cangrelor −10.76 −14.50 2.1339E-11 10.67
Asinex 1 (R) −9.06 −10.07 3.8842E-08 7.41
Asinex 1 (S) −8.91 −9.44 1.1296E-07 6.95
SPR Experiments
GPCRs are typically highly unstable when extracted from the cell
membranes, making them particularly difficult to study for ligand
screening with biophysical methods. Here, we used an effective
protocol which allowed us to extract from crude membranes
two engineered variants of GPR17 that are relatively stable in
the ligand-free state, and to immobilize them on the surface of
a sensor chip for SPR analysis. The SPR results obtained with
the high affinity antagonist Cangrelor and the agonist Asinex 1
demonstrated that the immobilized GPR17-T4 variants retained
their ability to specifically bind the analytes. Full kinetic analysis
of the agonist Asinex 1 and the antagonist Cangrelor, when
binding to GPR17-T4 (constructs 1–339 and 16–339) is shown in
Figure 3, with calculated binding parameters listed in the table.
Although the ratio between Cangrelor and Asinex 1 affinities
measured by SPR is similar to that reported in the literature
(Abbracchio et al., 2006; Ciana et al., 2006; Eberini et al., 2011)
(9.35 vs. 7), the absolute Kd values are 20–30 times higher in the
SPR experiments. This discrepancy might be ascribed to some
residual non-specific binding to GPR17-T4, due to the injection
of crudemembrane preparation, which could affect the calculated
Kd values. In addition, a perfect correspondence should not
be expected because SPR technique provides direct binding
data, whereas the literature data refer to a functional assay that
evaluates the ability of the agonist (Asinex 1) to increase the
binding of [35S]GTPγS to the activated receptor or the ability
of the antagonist (Cangrelor) to counteract the effect induced
by either Asinex 1 (Eberini et al., 2011) and a reference agonist
(Ciana et al., 2006).
Interestingly, the affinity of both ligands toward the full-length
GPR17-T4 1–339 is higher (ca. 50 times) with respect to that of
the N-terminal truncated form (construct 16–339), suggesting
a possible role of the N-terminal region in the binding with
the receptor.
In vitro Assays on Primary OPCs
Asinex 1 Inhibits Forskolin-Stimulated Adenylyl
Cyclase Activity in Primary OPCs
Tests in the previous paragraphs have demonstrated
proportionality between the affinity data evaluated, by
docking chemical compounds to the binding site of a GPR17
structure shaped by homology modeling, and binding data
measured in vitro, with such an instrumental approach as
SPR in which only the target protein is involved. The further
development was to demonstrate proportionality between
the above findings and the biological response. The first step
involved an in vitro test performed on cells and measuring an
early effect of the downstream signaling pathway activation.
The effects of Asinex 1 on adenylyl cyclase activity was
evaluated in primary purified OPC cultures. In line with
previous data obtained for GPR17 endogenous agonists, also
the synthetic compound Asinex 1 concentration-dependently
inhibited forskolin-stimulated cAMP formation with an
EC50 value of 6.5 ± 0.8 nM (Figure 4A). Moreover, this
effect was competitively antagonized by Cangrelor (IC50
10.2 ± 0.8 nM), suggesting a specific involvement of GPR17
(Figure 4B). These results are consistent with data reported
by our group in cells transfected with GPR17 (Eberini et al.,
2011) and further confirm that Asinex 1 interacts with the
same GPR17 nucleotide binding site recognized by the
endogenous ligands UDP and UDP-glucose (Ciana et al.,
2006).
Effects of GPR17 Activation by Asinex 1 on OPC
Maturation and Myelination
The second step was again an in vitro test in culture but
involved cells of two different lineages and targeted a more
complex and more delayed outcome of GPCR stimulation. Thus,
we evaluated whether Asinex 1 can promote myelination in
vitro, based on previous data showing that GPR17 activation
by endogenous ligands accelerates OPC differentiation toward
a mature phenotype (Fumagalli et al., 2011). In order to
verify whether also the synthetic GPR17 ligand Asinex 1 has
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FIGURE 3 | SPR analyses of ligand binding. Full kinetic analysis of the agonist Asinex 1 (A,B) and the antagonist Cangrelor (C,D) binding to GPR17-T4 1–339 and
GPR17-T4 16–339, with the determined binding parameters listed in the table.
myelinating properties, we tested this compound in purified
OPCs, cultured alone and in the presence of DRG neurons.
The endogenous ligands UDP and LTD4 were selected as
reference compounds. As shown in Figure 4, Asinex 1, tested
at nanomolar concentrations, strongly increased the percentage
of mature myelin basic protein (MBP+)-cells in primary OPCs
(CTRL: 100 ± 5.53%; LTD4 200 nM: 171.0 ± 21.70%; ASN1
1 nM: 166.5 ± 16.21%; ASN1 10 nM: 158.3 ± 15.77%)
(Figure 4C), and promoted the formation of myelinated axons,
as shown by increased “Myelination Index” in OPC-DRG co-
cultures (Figure 4D) (CTRL: 100 ± 12.10%; UDP: 193.9 ±
32.31%; ASN1 10 nM: 240.3 ± 64.43%), compared to vehicle-
treated control. Overall, these data indicate that, by acting on
GPR17 receptor, Asinex 1 is able to foster OPC maturation, as
also confirmed by appearance of a myelinating phenotype in
culture (Figures 4E,F).
DISCUSSION
SPR is a versatile and powerful technique formeasuring the direct
binding between an immobilized protein and its ligands. It is
emerging in the last years as one of the most popular approaches
in fragment-based drug discovery, due to the possibility to
perform rapid and cost-effective high throughput screenings
of fragment libraries. Among others, a great advantage of this
method is the need for extremely low amounts of both target
proteins and ligands, which makes it very useful in case of
proteins, such as membrane protein, that are difficult to produce
and purify. Several strategies have been developed to immobilize
membrane proteins onto the sensor chip, including trapping the
protein on a hydrophobic surface mimicking a membrane-like
environment (e.g., lipid bilayers or nanodiscs) (Karlsson and
Löfås, 2002; Glück et al., 2011). Alternatively, the tagged receptor
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FIGURE 4 | Functional validation of and SPR data on primary OPCs. (A) Inhibition of forskolin-stimulated adenylyl cyclase activity in primary OPCs by graded
concentrations (0.1–50 nM) of the GPR17 agonist Asinex 1 (ASN 1). (B) The GPR17 antagonist Cangrelor concentration-dependently counteracts ASN 1-mediated
(Continued)
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FIGURE 4 | inhibition of forskolin-stimulated adenylyl cyclase activity in primary OPCs. Cangrelor was used in the presence of a constant ASN 1 concentrations of
10 nM. Results are expressed with reference to forskolin-stimulated cAMP levels, set to 100%. Data represent the mean ± S.E. (error bars) of three separate
experiments, each performed in duplicate. (C) Representative images of CTRL, LTD4-, ASN 1- (1 and 10 nM) treated OPCs, showing cell labeling with anti-MBP
antibody (in red). Nuclei were labeled with Hoechst 33258 dye (HOE, in blue). Scale bars: 45µm. (D) Representative images of control (CTRL), UDP- and
ASN1-treated OPC-DRG co-cultures showing double immunostaining for anti-MBP antibody (red) and anti-neurofilament antibody (NF, green). Yellow color shows
co-staining. Scale bars: 20µm. (E) Histograms show quantification of the percentage of MBP+ cells in control and treated cells (with vehicle-treated control cells set
to 100%) for OPC cultures. The number of positive cells was counted in 20 optical fields under a 20× magnification. Data are the mean ± S.E. of three independent
experiments. *p < 0.05; **p < 0.01 compared to control; non-parametric Mann Whitney test. (F) Histograms show the quantification of the myelin segments,
calculated as the ratio between the white pixels area and the green pixels’ area (Myelination Index), for OPC-DRG co-cultures. Data are the mean ± S.E. of the index
obtained from the analysis of six random fields of three coverslips for each experimental condition from three independent experiments. *p < 0.05, Student’s t-test.
can be captured by a specific antibody immobilized on the chip
surface or via Ni-mediated affinity capturing (Chu et al., 2015).
A major issue in SPR analyses of membrane protein is the
retention of the native conformation and binding properties of
the immobilized target, and this is particularly true for GPCRs.
Here we have successfully immobilized two engineered variants
of the GPR17 receptor designed for crystallographic studies,
GPR17-T4 1–339 andGPR17-T4 16–339, and have analyzed their
binding with two high affinity ligands: the antagonist Cangrelor
and the agonist Asinex 1. The two GPR17 constructs can be
effectively extracted and solubilized in detergent solution, and
retain good monodispersity and activity even in the ligand-free
form, a mandatory prerequisite for SPR analysis. We set up a
protocol for single-step immobilization of the receptor on the
sensor chip through a covalently-bound anti-His6-antibody. The
protein was captured directly from the detergent solubilized
membrane extracts, avoiding the costly and time-consuming
purification of the receptor. The receptor retained its ligand
binding activity for over 24 h when immobilized on the chip, thus
allowing the design of fast screening experiments with fragment
libraries (i.e., with a single injection for each compound) for the
identification of new potential ligands. Furthermore, the use of
a covalently immobilized antibody makes possible, after a mild
regeneration step to remove the bound receptor, to reuse many
times the same chip just re-capturing a new batch of freshly
solubilized protein.
The affinity constants of the engineered full length receptor
(GPR17-T4 1–339) that we have determined by SPR are in good
agreement with that previously estimated for both ligands with
an indirect binding assay ([35S]GTPγS) on in mammalian cells
transfected with wild-type GPR17. It is worth noting that the
affinity of GPR17-T4 16–339, lacking the first 15 residues, is
substantially lower (about 50 times) compared to that of the full-
length variant, hinting to a functional role of some N-terminal
residues in ligand binding. The involvement of few residues of
this region (Leu4 and Val6) in ligand recognition was already
proposed in a previous computational study aimed at identifying
new ligands for GPR17 (Eberini et al., 2011). Overall, our new
docking/MD simulations, together with the SPR experimental
results, strengthen this hypothesis and allow us to speculate on
the importance of the N-terminal on GPR17 signaling. Of note,
the relative ranking of the affinities of the two ligands obtained
through the different assays, is inverted. This might be due to the
different sensitivity of the various assays in which the affinity is
measured, i.e., computational simulations in a 3D model or SPR
experiments in a non-physiological system. Moreover, as already
reported, the use of empirical scoring functions for estimating
dissociation constant values has accuracy in the range of one
order of magnitude (Eberini et al., 2008; Galli et al., 2014).
To confirm the validity of our approach for the identification
of new GPR17 ligands to be exploited in vivo in demyelinating
disorders, we performed a series of functional assays on a cell
system natively expressing GPR17, e.g., primary rat OPCs grown
in culture alone or in co-culture with neurons (Fumagalli et al.,
2011, 2015). Our data confirm that Asinex 1 is indeed a full
agonist at GPR17 acting on the nucleotide binding site of the
receptor (Eberini et al., 2011), as shown by the inhibition of
cAMP formation, the antagonism by Cangrelor, and the ability
to promote OPC maturation and differentiation.
Taken together, the results presented in this work demonstrate
that our protocol provides an effective and reliable way to
measure the direct binding of GPR17 even in the sub-nanomolar
range, and will be implemented for the systematic identification
of new active compounds on this important pharmacological
target. More generally, our findings confirm the potential of this
technique, in combination with complex in silico analyses and
functional assays on native systems, for evaluating the activity
of agonist and antagonist ligands on GPRCs, a family of crucial
targets in pharmacological research.
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